Here are the DEF 14A proxy statements from Tharimmune, Inc. (THAR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow THAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THAR filings page.
Tharimmune, Inc. has called a virtual special stockholder meeting for January 30, 2026 to vote on board changes and significant equity-related actions. Stockholders will elect two new directors, regulatory veteran Jill Sommers and capital markets executive William Wiley, replacing James Gordon Liddy upon approval. The record date is December 3, 2025, when 36,444,785 common shares were outstanding and entitled to vote.
Investors are asked to approve issuances tied to several prior financings and advisory arrangements. These include shares issuable on exercise of Strategic Advisor Warrants equal to 5.0% of fully diluted common stock at a nominal exercise price, Cryptocurrency Pre-Funded Warrants received for Canton Coin cryptocurrency, and Advisor RSUs and related shares for the placement agent. The meeting will also consider adding 7,000,000 shares to the 2023 Omnibus Equity Incentive Plan and authorizing potential adjournments if support is initially insufficient.